- June 1, 2018
- Posted by: PharmaScroll
- Category:
A recent article, published in Annals of Clinical and Translational Neurology, states that use of corticosteroids and inosine monophosphate dehydrogenase inhibitors might lower the risk of Parkinson disease. The study conducted was a targeted pharmacoepidemiology analysis to investigate the risk of PD in relation to immunosuppressant use.
The study was a population‐based case–control study using Medicare claims data from the United States (U.S.), following approval from the Centers for Medicare and Medicaid (CMS), and the Institutional Review Board at Washington University in St. Louis. All participants were U.S. residents who were age 66–90 years old and relied solely on Medicare for health insurance (Parts A/B) in 2009. For the analysis, the researchers further focused on beneficiaries with Medicare Part D (pharmacy) coverage with at least one prescription drug claim (medication fill) in 2008–2009.
Among beneficiaries who met these criteria, the researchers determined PD status from comprehensive (inpatient, skilled nursing facility, outpatient, physician/carrier, durable medical equipment, and home health care) Part A and B Medicare claims data for 2004–2009. PD cases (n = 48,295) had at least one International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9) diagnosis code for PD (332 or 332.0) in 2009 and no prior PD codes. Controls (n = 52,324) were from a random sample of beneficiaries who met the same criteria, but without PD codes. These beneficiaries represented 54% of cases and 44% of controls from the original case–control study, which included all newly diagnosed PD cases in 2009 and a 0.5% random sample of all noncases who met study criteria.
Results of the study:
Inosine monophosphate dehydrogenase inhibitors (relative risk = 0.64; 95% confidence interval 0.51–0.79) and corticosteroids (relative risk = 0.80; 95% confidence interval 0.77–0.83) were both associated with a lower risk of Parkinson disease. Inverse associations for both remained after applying a 12‐month exposure lag. Overall, the study concluded that there is an evidence that use of corticosteroids and inosine monophosphate dehydrogenase inhibitors might lower the risk of Parkinson disease.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Parkinson’s disease indication, visit https://pharmascroll.com/news-category/parkinsons/
News Source: https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.580
Image Source: http://www.parkinsonalabama.com/5-tips-educating-patients-parkinsons-disease/